Cost utility analysis of the SQ® HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting

Table 3 Summary of utility values applied to patients in the analysis

Utility at baseline—all patients	Change from baseline			Utility adopted in analysis
Utility at baseline—all patients	Placebo	ACARIZAX	p value	Placebo	ACARIZAX
0.736	0.0059	0.0315	0.0318	0.742	0.768

Within MT-04 patient utility was measured using the SF-36 survey instrument. There was a statistically significant difference in utility change (i.e. a measurement of patient quality of life) from baseline to the end of the treatment maintenance period in MT-04 between ACARIZAX and placebo (p < 0.05). These values were applied to the mean utility score at baseline for all patients, to estimate the values that were applied at baseline in the analysis. Overall, ACARIZAX patients had a greater quality of life compared to placebo patients, at the end of the treatment maintenance period

ISSN: 2045-7022